Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy
Conditions: Ovarian Cancer; Carcinosarcoma Intervention: Drug: Pamiparib Sponsor: Australia New Zealand Gynaecological Oncology Group Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Australia Health | Cancer | Cancer & Oncology | Carcinosarcoma | Chemotherapy | Genetics | New Zealand Health | OBGYN | Ovarian Cancer | Ovaries | Research